



GUFIC BIOSCIENCES LIMITED Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069 AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31.03.2015					
	Rs. In Lacs				
Particulars	Quarter Ended 31.03.2015 Audited	Quarter Ended 31.03.2014 Audited	Quarter Ended 31.12.2014 Unaudited	For the Year Ended 31.03.2015 Audited	For the Year Ended 31.03.2014 Audited
INCOME:					
Net Sales / Income from Operations (Net of Excise Duty)	3547.55	3722.33	3423.19	15142.61	12291.58
Other Operating Income	6.90	13.86	10.99	32.53	22.92
Total Income from Operations (Net)	3554.46	3736.19	3434.18	15175.14	12314.50
EXPENSES:					
Cost of Materials Consumed	1133.87	1541.87	1536.51	6579.76	5194.33
Purchase of Stock-in-Trade	472.44	473.35	372.16	1670.77	1377.03
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	149.49	144.48	(229.61)	(130.68)	40.87
Employee Benefits Expenses	647.57	368.09	460.44	1933.33	1194.34
Depreciation and Amortisation Expenses	77.29	64.63	105.57	385.21	246.77
Other Expenses	867.28	877.33	950.54	3675.26	3291.42
Total Expenses	3347.94	3469.74	3195.61	14113.66	11344.75
Profit from Operations before Other Income, finance costs and Exceptional Items	206.52	266.45	238.56	1061.48	969.75
Other Income	21.28	34.20	(1.46)	37.18	49.15
Profit from ordinary activities before finance costs and exceptional items	227.80	300.65	237.10	1098.66	1018.90
Finance Costs	127.87	102.04	101.42	446.08	391.57
Profit from ordinary activities after finance costs but before exceptional items	99.93	198.62	135.68	652.59	627.32
Exceptional Items	0.00	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	99.93	198.62	135.68	652.59	627.32
Current Tax	18.50	41.93	81.50	278.61	151.00
Deferred Tax	(32.14)	(11.70)	(12.79)	(48.84)	7.01
Short/(Excess) Tax Provisions of Earlier Years	3.34	42.90	(0.69)	7.08	42.90
Net Profit from Ordinary Activities After Tax	110.23	125.49	67.66	415.74	426.41
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00
Net Profit for the Period	110.23	125.49	67.66	415.74	426.41
 Paid up Equity Share Capital (Face Value of Rs 1 /- Each)	 773.50	 773.50	 773.50	 773.50	 773.50
Reserves Excluding Revaluation Reserves	1936.49	1847.35	1864.57	1936.49	1847.35
E.P.S	0.14	0.16	0.09	0.54	0.55
Public Shareholding					
-- Number of Shares of Rs 1 /- Each	23222355	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%
Promoters and Promoter group Shareholding					
a) Pledged / Encumbered					
-- Number of Shares of Rs 1 /- Each	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered					
-- Number of Shares of Rs 1 /- Each	54127645	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 29th May, 2015. The Financial Results have been Audited by the Statutory Auditor of the Company

Place: Mumbai
Date: 29.05.2015

For GUFIC BIOSCIENCES LTD

 Jayesh P. Choksi
 Managing Director



GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

AUDITED SEGMENT WISE RESULTS FOR THE QUARTER / YEAR ENDED 31.03.2015

Particulars	Quarter Ended 31.03.2015 Audited	Quarter Ended 31.03.2014 Audited	Quarter Ended 31.12.2014 Unaudited	For the Year Ended 31.03.2015 Audited	For the Year Ended 31.03.2014 Audited
SEGMENT REVENUE					
Sales & Service					
Pharma	3213.91	3385.00	3253.27	13922.95	11051.26
Consumer	333.65	337.34	169.91	1219.66	1240.32
Total	3547.56	3722.34	3423.19	15142.61	12291.58
Unallocabel Income	28.18	48.06	9.52	69.71	72.07
Total Segment Revenue	3575.74	3770.40	3432.71	15212.32	12363.65
SEGMENT RESULTS					
Pharma	612.79	680.02	634.39	2701.05	2144.25
Consumer	43.41	63.14	17.94	136.97	238.83
TOTAL	656.20	743.16	652.33	2838.02	2383.08
Less: Unallocated over heads	351.11	377.88	309.66	1354.15	1117.41
Finance Charges	127.87	102.04	101.42	446.08	391.57
Depreciation	77.29	64.63	105.57	385.21	246.77
Tax provision	(10.30)	73.13	68.02	236.85	200.91
Net Profit after Tax	110.23	125.49	67.66	415.74	426.41

AUDITED STATEMENT OF ASSETS AND LIABILITIES

Particulars	AS AT 31.03.2015 Audited	AS AT 31.03.2014 Audited
EQUITY AND LIABILITIES		
Shareholder's Funds		
a) Share Capital	773.50	773.50
b) Reserves and Surplus	1,936.49	1,847.37
Sub-total - Shareholder's Funds	2709.99	2620.87
Non-current liabilities		
a) Long-term borrowings	1,150.34	1,488.81
b) Deferred tax liabilities (Net)	154.73	301.69
c) Other long-term liabilities	212.27	536.88
d) Long-term provisions	140.50	135.29
Sub-total - Non-current liabilities	1657.84	2462.68
Current liabilities		
a) Short-term borrowings	1,790.42	1,476.64
b) Trade payables	4,953.33	3,179.63
c) Other current liabilities	1,301.23	1,127.69
d) Short-term provisions	315.97	247.07
Sub-total - Current liabilities	8360.95	6031.03
TOTAL - EQUITY AND LIABILITIES	12728.78	11114.58
ASSETS		
Non-current assets		
a) Fixed assets	2,510.71	3,022.87
b) Non-current investments	0.93	0.93
c) Long-term loans and advances	759.75	833.65
d) Other non-current assets	282.58	326.69
Sub-total - Non-Current assets	3553.97	4184.14
Current assets		
a) Current investments		
b) Inventories	3,680.14	2,611.54
c) Trade receivables	3,324.30	2,820.71
d) Cash and cash equivalents	620.63	254.15
e) Short-term loans and advances	1,549.74	1,244.04
f) Other current assets		
Sub-total - Current assets	9174.81	6930.44
TOTAL - ASSETS	12728.78	11114.58

For GUFIC BIOSCIENCES LIMITED




JAYESH P. CHOKSI
Managing Director

Notes forming part of the Audited financial results for the quarter ended March 31, 2015

1. The above interim financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on May 29, 2015.
2. For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2014, except for accounting of depreciation on fixed assets.
3. As per the requirement of the Companies Act, 2013 (Act), the company has reassessed the remaining useful life of the fixed assets taking into consideration the useful life prescribed in Schedule II of the Act. The written down value of the assets of Rs. 280.07 Lacs as on April 1, 2014 (net of deferred tax of Rs. 98.12 Lacs) whose residual life is exhausted has been adjusted against the opening balance of Reserves and Surplus.
4. The figures of the last quarter of financial year 2014-15 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2015 and the unaudited published year – to – date figures upto December 31, 2014 which were subject to limited review.
5. The Board of Directors at its meeting held on May 29, 2015 has recommended a final dividend of Rs. 0.05 per equity shares. This proposal is subject to approval of shareholders at the ensuing Annual General Meeting.
6. Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on March 31, 2015: Nil.
7. Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

By Order of the Board
Gufic Biosciences Limited


Jayesh P. Choksi
Managing Director
Mumbai dated May 29, 2015

